Trial · NCT01564277
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Probability of Obtaining a Uric Acid Level =< 7.5mg/dL | Arm I (1.5mg Rasburicase) | 0.83 | 95% Confidence Interval 0.52 to 0.98 | proportion of participants | |
| Probability of Obtaining a Uric Acid Level =< 7.5mg/dL | Arm II (3 mg Rasburicase) | 0.67 | 95% Confidence Interval 0.35 to 0.90 | proportion of participants | |
| Number of Patients Requiring Additional Doses of Rasburicase to Maintain a Uric Acid Level =< 7.5mg/dL | Arm I (1.5mg Rasburicase) | 1 | Participants | ||
| Number of Patients Requiring Additional Doses of Rasburicase to Maintain a Uric Acid Level =< 7.5mg/dL | Arm II (3 mg Rasburicase) | 3 | Participants | ||
| Baseline White Blood Cell Count by Response | Arm I (1.5mg Rasburicase) | Complete Response | 62.1 | Standard Deviation 32.3 | cells x 10^9/L |
| Baseline White Blood Cell Count by Response | Arm II (3 mg Rasburicase) | Complete Response | 29.0 | Standard Deviation 34.0 | cells x 10^9/L |
| Baseline White Blood Cell Count by Response | Arm I (1.5mg Rasburicase) | No Complete Response | 13.9 | Standard Deviation 17.1 | cells x 10^9/L |
| Baseline White Blood Cell Count by Response | Arm II (3 mg Rasburicase) | No Complete Response | 33.3 | Standard Deviation 19.0 | cells x 10^9/L |
| Area Under the Plasma Uric Acid Concentration-time Curve (AUC) From Baseline (Day 1) to Day 7 | Arm I (1.5mg Rasburicase) | 12.5 | Standard Deviation 9.0 | days*mg/dL | |
| Area Under the Plasma Uric Acid Concentration-time Curve (AUC) From Baseline (Day 1) to Day 7 | Arm II (3 mg Rasburicase) | 3.5 | Standard Deviation 4.7 | days*mg/dL | |
| Safety of Low Single-doses of Rasburicase. | Arm I (1.5mg Rasburicase) | 12 | Participants | ||
| Safety of Low Single-doses of Rasburicase. | Arm II (3 mg Rasburicase) | 12 | Participants | ||
| Number of Patients Experiencing a Doubling of Serum Creatinine | Arm I (1.5mg Rasburicase) | 0 | Participants | ||
| Number of Patients Experiencing a Doubling of Serum Creatinine | Arm II (3 mg Rasburicase) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01564277/results